Garde Capital Inc. Takes $140,000 Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Garde Capital Inc. acquired a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 1,085 shares of the biotechnology company’s stock, valued at approximately $140,000.

Several other large investors also recently modified their holdings of the stock. Capital International Investors lifted its holdings in Sarepta Therapeutics by 160.0% during the 4th quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company’s stock worth $457,221,000 after buying an additional 2,917,797 shares in the last quarter. Farallon Capital Management LLC lifted its stake in shares of Sarepta Therapeutics by 102.8% in the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after purchasing an additional 1,243,427 shares during the period. Norges Bank acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at $80,697,000. Bank of Nova Scotia acquired a new stake in Sarepta Therapeutics during the 4th quarter worth $50,990,000. Finally, Avoro Capital Advisors LLC raised its stake in Sarepta Therapeutics by 7.9% during the 4th quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock worth $418,935,000 after buying an additional 319,444 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Mizuho increased their target price on Sarepta Therapeutics from $145.00 to $179.00 and gave the stock a “buy” rating in a report on Friday, May 17th. Morgan Stanley reiterated an “overweight” rating and set a $165.00 target price on shares of Sarepta Therapeutics in a report on Friday, June 21st. Bank of America raised their price objective on Sarepta Therapeutics from $166.00 to $213.00 and gave the company a “buy” rating in a report on Friday, June 21st. Robert W. Baird raised their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, June 21st. Finally, BMO Capital Markets raised their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a report on Monday, June 24th. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $187.72.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT traded down $0.07 during midday trading on Friday, reaching $143.94. 1,181,646 shares of the company were exchanged, compared to its average volume of 1,187,754. The stock’s 50-day moving average price is $139.35 and its 200-day moving average price is $130.75. The stock has a market cap of $13.61 billion, a P/E ratio of 1,308.55 and a beta of 0.89. Sarepta Therapeutics, Inc. has a one year low of $55.25 and a one year high of $173.25. The company has a quick ratio of 3.44, a current ratio of 4.05 and a debt-to-equity ratio of 1.18.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.84. The firm had revenue of $413.50 million for the quarter, compared to analysts’ expectations of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The company’s revenue was up 63.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.44) earnings per share. On average, sell-side analysts anticipate that Sarepta Therapeutics, Inc. will post 3.76 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Bilal Arif sold 7,859 shares of the business’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $163.08, for a total value of $1,281,645.72. Following the sale, the insider now owns 21,261 shares of the company’s stock, valued at $3,467,243.88. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, EVP Ryan Edward Brown sold 38,957 shares of the business’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total value of $6,295,840.77. Following the transaction, the executive vice president now owns 17,129 shares in the company, valued at $2,768,217.69. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Bilal Arif sold 7,859 shares of the business’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the completion of the transaction, the insider now owns 21,261 shares in the company, valued at approximately $3,467,243.88. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.